Next Article in Journal
Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages
Previous Article in Journal
Prospects for Anti-Biofilm Pharmaceuticals
Previous Article in Special Issue
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2015, 8(3), 512-524; doi:10.3390/ph8030512

Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study

1
Norwich Medical School, University of East Anglia, Norwich 06360, UK
2
Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich 06360, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Jane McHowat
Received: 23 July 2015 / Revised: 16 August 2015 / Accepted: 25 August 2015 / Published: 7 September 2015
(This article belongs to the Special Issue Non-Steroidal Anti-Inflammatory Drugs)
View Full-Text   |   Download PDF [679 KB, uploaded 7 September 2015]

Abstract

Patients with inflammatory bowel disease (IBD) often have associated conditions, for which anti-inflammatory medication with cyclo-oxygenase (COX) inhibitors may be helpful. The current evidence is conflicting regarding the role of COX-inhibitors in causing relapse in IBD. This case-control study examined the association between the use of COX inhibitors and relapse of IBD. Logistic regression was used to analyse the relationship between COX-inhibitors and IBD relapse. Overall COX inhibitor use (combined non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 agents) had a negative association with relapse of IBD (adjusted OR 0.26, 95% CI 0.09–0.80). This negative association was confined to ulcerative colitis (UC) (adjusted OR = 0.06, 95% CI 0.01–0.50) and no association was found in Crohn’s disease (CD) patients (adjusted OR 1.25, 95% CI 0.18–7.46). The significant negative association between UC relapse and medication use was also seen with non-specific NSAIDs. Selective COX-2 inhibitor use was rare but non-significantly more common in stable patients. There was no association between low-dose aspirin or paracetamol use and relapse of CD or UC. We conclude that COX-inhibitor use was not associated with an increased risk of relapse in UC or CD, and may be protective in UC. Where indicated, NSAIDs should not be withheld from IBD patients. View Full-Text
Keywords: Crohn’s disease; Ulcerative colitis; cyclo-oxygenase; non-steroidal anti-inflammatory drug Crohn’s disease; Ulcerative colitis; cyclo-oxygenase; non-steroidal anti-inflammatory drug
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hensley, A.; Beales, I.L.P. Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals 2015, 8, 512-524.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top